The Ras Inhibitors Caveolin-1 and Docking Protein 1 Activate Peroxisome Proliferator-Activated Receptor γ through Spatial Relocalization at Helix 7 of Its Ligand-Binding Domain

REFERENCES

• Agostini, M., et al. 2004. Tyrosine agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor gamma. Endocrinology 145:1527–1538.
   PubMedGoogle Scholar
• Barresi, V., G. Giuffre, E. Vitarelli, P. Todaro, and G. Tuccari. 2008. Caveolin-1 immuno-expression in human gastric cancer: histopathogenetic hypotheses. Virchows Arch. 453:571–578.
   PubMedGoogle Scholar
• Berger, A. H., et al. 2010. Identification of DOK genes as lung tumor suppressors. Nat. Genet. 42:216–223.
   PubMedGoogle Scholar
• Burgermeister, E., et al. 2007. Interaction with MEK causes nuclear export and downregulation of peroxisome proliferator-activated receptor gamma. Mol. Cell. Biol. 27:803–817.
   PubMedGoogle Scholar
• Burgermeister, E., et al. 2006. A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) recruits PPARgamma-coactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro. Mol. Endocrinol. 20:809–830.
   PubMed Web of Science ®Google Scholar
• Burgermeister, E., and R. Seger. 2007. MAPK kinases as nucleo-cytoplasmic shuttles for PPARgamma. Cell Cycle 6:1539–1548.
   PubMed Web of Science ®Google Scholar
• Burgermeister, E., and R. Seger. 2008. PPARgamma and MEK Interactions in Cancer. PPAR Res. 2008:309469.
   PubMedGoogle Scholar
• Burgermeister, E., L. Tencer, and M. Liscovitch. 2003. Peroxisome proliferator-activated receptor-gamma upregulates caveolin-1 and caveolin-2 expression in human carcinoma cells. Oncogene 22:3888–3900.
   PubMed Web of Science ®Google Scholar
• Burgermeister, E., et al. 2007. Differential expression and function of caveolin-1 in human gastric cancer progression. Cancer Res. 67:8519–8526.
   PubMedGoogle Scholar
• Chen, X., et al. 2010. Integrin alpha1beta1 regulates epidermal growth factor receptor activation by controlling peroxisome proliferator-activated receptor gamma-dependent caveolin-1 expression. Mol. Cell. Biol. 30:3048–3058.
   PubMedGoogle Scholar
• Choi, J. H., et al. 2010. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature 466:451–456.
   PubMed Web of Science ®Google Scholar
• Chuderland, D., A. Konson, and R. Seger. 2008. Identification and characterization of a general nuclear translocation signal in signaling proteins. Mol. Cell 31:850–861.
   PubMed Web of Science ®Google Scholar
• Couet, J., S. Li, T. Okamoto, T. Ikezu, and M. P. Lisanti. 1997. Identification of peptide and protein ligands for the caveolin-scaffolding domain. Implications for the interaction of caveolin with caveolae-associated proteins. J. Biol. Chem. 272:6525–6533.
   PubMed Web of Science ®Google Scholar
• Couet, J., M. Sargiacomo, and M. P. Lisanti. 1997. Interaction of a receptor tyrosine kinase, EGF-R, with caveolins. Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities. J. Biol. Chem. 272:30429–30438.
   PubMed Web of Science ®Google Scholar
• Demers, A., et al. 2009. A concerted kinase interplay identifies PPARgamma as a molecular target of ghrelin signaling in macrophages. PLoS One 4:e7728.
   PubMedGoogle Scholar
• Ebert, M. P., et al. 2006. Identification and confirmation of increased fibrinopeptide a serum protein levels in gastric cancer sera by magnet bead assisted MALDI-TOF mass spectrometry. J. Proteome Res. 5:2152–2158.
   PubMedGoogle Scholar
• Gampe, R. T.Jr., et al. 2000. Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors. Mol. Cell 5:545–555.
   PubMed Web of Science ®Google Scholar
• Gratton, J. P., et al. 2003. Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice. Cancer Cell 4:31–39.
   PubMed Web of Science ®Google Scholar
• Gupta, R. A., et al. 2001. Activation of peroxisome proliferator-activated receptor gamma suppresses nuclear factor kappa B-mediated apoptosis induced by Helicobacter pylori in gastric epithelial cells. J. Biol. Chem. 276:31059–31066.
   PubMed Web of Science ®Google Scholar
• Han, S., N. Sidell, P. B. Fisher, and J. Roman. 2004. Up-regulation of p21 gene expression by peroxisome proliferator-activated receptor gamma in human lung carcinoma cells. Clin. Cancer Res. 10:1911–1919.
   PubMed Web of Science ®Google Scholar
• He, Q., J. Chen, H. L. Lin, P. J. Hu, and M. H. Chen. 2007. Expression of peroxisome proliferator-activated receptor gamma, E-cadherin and matrix metalloproteinases-2 in gastric carcinoma and lymph node metastases. Chin. Med. J. (Engl.). 120:1498–1504.
   PubMedGoogle Scholar
• Hegele, R. A., H. Cao, C. Frankowski, S. T. Mathews, and T. Leff. 2002. PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy. Diabetes 51:3586–3590.
   PubMed Web of Science ®Google Scholar
• Holt, J. A., et al. 2003. Helix 1/8 interactions influence the activity of nuclear receptor ligand-binding domains. Mol. Endocrinol. 17:1704–1714.
   PubMedGoogle Scholar
• Hosooka, T., et al. 2008. Dok1 mediates high-fat diet-induced adipocyte hypertrophy and obesity through modulation of PPAR-gamma phosphorylation. Nat. Med. 14:188–193.
   PubMedGoogle Scholar
• Hubert, P., V. Ferreira, P. Debre, and G. Bismuth. 2000. Molecular cloning of a truncated p62Dok1 isoform, p22Dok(del). Eur. J. Immunogenet. 27:145–148.
   PubMedGoogle Scholar
• Karapetis, C. S., et al. 2008. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359:1757–1765.
   PubMed Web of Science ®Google Scholar
• Kawai, M., et al. 2010. A circadian-regulated gene, Nocturnin, promotes adipogenesis by stimulating PPAR-gamma nuclear translocation. Proc. Natl. Acad. Sci. U. S. A. 107:10508–10513.
   PubMed Web of Science ®Google Scholar
• Kelly, D., et al. 2004. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA. Nat. Immunol. 5:104–112.
   PubMed Web of Science ®Google Scholar
• Kobayashi, R., R. Patenia, S. Ashizawa, and J. Vykoukal. 2009. Targeted mass spectrometric analysis of N-terminally truncated isoforms generated via alternative translation initiation. FEBS Lett. 583:2441–2445.
   PubMedGoogle Scholar
• Lefebvre, A. M., et al. 1998. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat. Med. 4:1053–1057.
   PubMed Web of Science ®Google Scholar
• Lehrke, M., and M. A. Lazar. 2005. The many faces of PPARgamma. Cell 123:993–999.
   PubMed Web of Science ®Google Scholar
• Leung, W. K., et al. 2004. Effect of peroxisome proliferator activated receptor gamma ligands on growth and gene expression profiles of gastric cancer cells. Gut 53:331–338.
   PubMed Web of Science ®Google Scholar
• Li, J., et al. 2005. Loss of caveolin-1 causes the hyper-proliferation of intestinal crypt stem cells, with increased sensitivity to whole body gamma-radiation. Cell Cycle 4:1817–1825.
   PubMed Web of Science ®Google Scholar
• Liu, J., H. Wang, Y. Zuo, and S. R. Farmer. 2006. Functional interaction between peroxisome proliferator-activated receptor gamma and beta-catenin. Mol. Cell. Biol. 26:5827–5837.
   PubMed Web of Science ®Google Scholar
• Llaverias, G., et al. 2004. Rosiglitazone upregulates caveolin-1 expression in THP-1 cells through a PPAR-dependent mechanism. J. Lipid Res. 45:2015–2024.
   PubMed Web of Science ®Google Scholar
• Lu, J., et al. 2005. Chemopreventive effect of peroxisome proliferator-activated receptor gamma on gastric carcinogenesis in mice. Cancer Res. 65:4769–4774.
   PubMedGoogle Scholar
• Mashima, R., Y. Hishida, T. Tezuka, and Y. Yamanashi. 2009. The roles of Dok family adapters in immunoreceptor signaling. Immunol. Rev. 232:273–285.
   PubMedGoogle Scholar
• Matthews, L., et al. 2008. Caveolin mediates rapid glucocorticoid effects and couples glucocorticoid action to the antiproliferative program. Mol. Endocrinol. 22:1320–1330.
   PubMedGoogle Scholar
• McAlpine, C. A., Y. Barak, I. Matise, and R. T. Cormier. 2006. Intestinal-specific PPARgamma deficiency enhances tumorigenesis in ApcMin/+ mice. Int. J. Cancer 119:2339–2346.
   PubMed Web of Science ®Google Scholar
• McCoy, M. S., C. I. Bargmann, and R. A. Weinberg. 1984. Human colon carcinoma Ki-ras2 oncogene and its corresponding proto-oncogene. Mol. Cell. Biol. 4:1577–1582.
   PubMed Web of Science ®Google Scholar
• Meza-Junco, J., H. J. Au, and M. B. Sawyer. 2009. Trastuzumab for gastric cancer. Expert Opin. Biol. Ther. 9:1543–1551.
   PubMed Web of Science ®Google Scholar
• Nakajima, A., et al. 2001. Endogenous PPAR gamma mediates anti-inflammatory activity in murine ischemia-reperfusion injury. Gastroenterology 120:460–469.
   PubMed Web of Science ®Google Scholar
• Niu, Y., et al. 2006. A nuclear export signal and phosphorylation regulate Dok1 subcellular localization and functions. Mol. Cell. Biol. 26:4288–4301.
   PubMedGoogle Scholar
• Nolte, R. T., et al. 1998. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 395:137–143.
   PubMed Web of Science ®Google Scholar
• Nomura, S., et al. 2006. Differential expression of peroxisome proliferator-activated receptor in histologically different human gastric cancer tissues. J. Exp. Clin. Cancer Res. 25:443–448.
   PubMedGoogle Scholar
• Parton, R. G., and K. Simons. 2007. The multiple faces of caveolae. Nat. Rev. Mol. Cell Biol. 8:185–194.
   PubMed Web of Science ®Google Scholar
• Pascual, G., et al. 2005. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 437:759–763.
   PubMed Web of Science ®Google Scholar
• Rajab, A., et al. 2010. Fatal cardiac arrhythmia and long-QT syndrome in a new form of congenital generalized lipodystrophy with muscle rippling (CGL4) due to PTRF-CAVIN mutations. PLoS Genet. 6:e1000874.
   PubMed Web of Science ®Google Scholar
• Razani, B., et al. 2002. Caveolin-1-deficient mice are lean, resistant to diet-induced obesity, and show hypertriglyceridemia with adipocyte abnormalities. J. Biol. Chem. 277:8635–8647.
   PubMed Web of Science ®Google Scholar
• Razani, B., et al. 2001. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J. Biol. Chem. 276:38121–38138.
   PubMed Web of Science ®Google Scholar
• Rim, J. S., B. Xue, B. Gawronska-Kozak, and L. P. Kozak. 2004. Sequestration of thermogenic transcription factors in the cytoplasm during development of brown adipose tissue. J. Biol. Chem. 279:25916–25926.
   PubMedGoogle Scholar
• Rumi, M. A., et al. 2004. Peroxisome proliferator-activated receptor gamma-dependent and -independent growth inhibition of gastrointestinal tumour cells. Genes Cells 9:1113–1123.
   PubMed Web of Science ®Google Scholar
• Sato, H., et al. 2000. Expression of peroxisome proliferator-activated receptor (PPAR)gamma in gastric cancer and inhibitory effects of PPARgamma agonists. Br. J. Cancer 83:1394–1400.
   PubMed Web of Science ®Google Scholar
• Schlegel, A., C. Wang, B. S. Katzenellenbogen, R. G. Pestell, and M. P. Lisanti. 1999. Caveolin-1 potentiates estrogen receptor alpha (ERalpha) signaling. caveolin-1 drives ligand-independent nuclear translocation and activation of ERalpha. J. Biol. Chem. 274:33551–33556.
   PubMedGoogle Scholar
• Sharma, C., A. Pradeep, R. G. Pestell, and B. Rana. 2004. Peroxisome proliferator-activated receptor gamma activation modulates cyclin D1 transcription via beta-catenin-independent and cAMP-response element-binding protein-dependent pathways in mouse hepatocytes. J. Biol. Chem. 279:16927–16938.
   PubMed Web of Science ®Google Scholar
• Shimada, T., et al. 2007. Peroxisome proliferator-activated receptor gamma (PPARgamma) regulates trefoil factor family 2 (TFF2) expression in gastric epithelial cells. Int. J. Biochem. Cell Biol. 39:626–637.
   PubMedGoogle Scholar
• Simha, V., and A. Garg. 2009. Inherited lipodystrophies and hypertriglyceridemia. Curr. Opin. Lipidol. 20:300–308.
   PubMedGoogle Scholar
• Stremmel, W., L. Pohl, A. Ring, and T. Herrmann. 2001. A new concept of cellular uptake and intracellular trafficking of long-chain fatty acids. Lipids 36:981–989.
   PubMed Web of Science ®Google Scholar
• Thompson, J., et al. 2000. A transgenic mouse line that develops early-onset invasive gastric carcinoma provides a model for carcinoembryonic antigen-targeted tumor therapy. Int. J. Cancer 86:863–869.
   PubMedGoogle Scholar
• van Beekum, O., V. Fleskens, and E. Kalkhoven. 2009. Posttranslational modifications of PPAR-gamma: fine-tuning the metabolic master regulator. Obesity (Silver Spring) 17:213–219.
   PubMed Web of Science ®Google Scholar
• von Knethen, A., et al. 2007. PPARgamma1 attenuates cytosol to membrane translocation of PKCalpha to desensitize monocytes/macrophages. J. Cell Biol. 176:681–694.
   PubMed Web of Science ®Google Scholar
• von Knethen, A., N. Tzieply, C. Jennewein, and B. Brune. 2010. Casein-kinase-II-dependent phosphorylation of PPARgamma provokes CRM1-mediated shuttling of PPARgamma from the nucleus to the cytosol. J. Cell Sci. 123:192–201.
   PubMedGoogle Scholar
• Wainberg, Z. A., et al. 2010. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin. Cancer Res. 16:1509–1519.
   PubMed Web of Science ®Google Scholar
• Wang, H., L. Qiang, and S. R. Farmer. 2008. Identification of a domain within peroxisome proliferator-activated receptor gamma regulating expression of a group of genes containing fibroblast growth factor 21 that are selectively repressed by SIRT1 in adipocytes. Mol. Cell. Biol. 28:188–200.
   PubMed Web of Science ®Google Scholar
• Wei, S., et al. 2008. A novel mechanism by which thiazolidinediones facilitate the proteasomal degradation of cyclin D1 in cancer cells. J. Biol. Chem. 283:26759–26770.
   PubMed Web of Science ®Google Scholar
• Xing, X., et al. 2009. Hematopoietically expressed homeobox is a target gene of farnesoid X receptor in chenodeoxycholic acid-induced liver hypertrophy. Hepatology 49:979–988.
   PubMed Web of Science ®Google Scholar
• Xu, W., et al. 2010. PPARgamma polymorphisms and cancer risk: a meta-analysis involving 32,138 subjects. Oncol. Rep. 24:579–585.
   PubMed Web of Science ®Google Scholar
• Yuasa, Y. 2003. Control of gut differentiation and intestinal-type gastric carcinogenesis. Nat. Rev. Cancer 3:592–600.
   PubMed Web of Science ®Google Scholar